ArticleClinical ophthalmology (Auckland, N.Z.)2026
Twelve‑month Response and Safety of Intravitreal Dexamethasone Implant in Treatment‑Naïve and Recalcitrant Cystoid Macular Edema Secondary to Branch Retinal Vein Occlusion (TREAT-BRVO Study).
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To compare anatomical and visual outcomes following dexamethasone intravitreal implant (Ozurdex) in treatment-naive versus recalcitrant cystoid macular edema (CME) secondary to branch retinal vein occlusion (BRVO). Patients and Methods: This retrospective study included 45 eyes with BRVO-related CME treated with Ozurdex and followed for 12 months. Eyes were classified as treatment-naive (n=13) if they received no prior treatment, including intravitreal therapy or laser photocoagulation. Eyes were classified as recalcitrant (n=32) if previously treated with at least three anti-vascular endothelial growth factor (anti-VEGF) agents. Primary outcomes were best-corrected visual acuity (BCVA) in logMAR and central macular thickness (CMT). Secondary outcomes included changes intraretinal fluid (IRF), subretinal fluid (SRF), hyperreflective intraretinal foci (HRIF), disorganization of retinal inner layers (DRIL), lens status, and retreatment rates. Results: Baseline BCVA and CMT were comparable between groups. A mean of 1.74±0.81 dexamethasone implants was administered, with no difference between groups. BCVA improved significantly from 0.625±0.262 to 0.299±0.14 logMAR at 12 months ( Conclusion: Intravitreal dexamethasone implant was associated with significant anatomical and functional improvements in both treatment-naïve and anti-VEGF refractory BRVO-related CME. While no statistically significant differences were identified between the groups, adequately powered prospective studies are required to determine whether treatment outcomes differ according to prior anti-VEGF exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.